Stay updated on Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial page.
Latest updates to the Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.1%
- Check19 days agoChange DetectedThe website has updated the contact details section for the study, replacing the previous information with new details and clarifying where the study is taking place.SummaryDifference3%
- Check26 days agoChange DetectedRecent updates include new entries for November 2024, while previous updates from July 2024 have been removed.SummaryDifference0.5%
- Check33 days agoChange DetectedThe website has added new features for user interaction while removing extensive details about participant groups, interventions, and various data fields available for download.SummaryDifference4%
- Check40 days agoChange DetectedSeveral key resources related to rare diseases and clinical trials have been removed, including links to NIH and Dailymed, which may impact access to important medical information.SummaryDifference0.5%
- Check48 days agoChange DetectedThe website has been updated to version 2.12.2, with new additions including links to clinical trials, drug information, and resources from NIH and HHS, while the previous version 2.12.1 has been removed.SummaryDifference5%
Stay in the know with updates to Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial page.